Neutralizing antibodies against SARS-CoV-2 variants following mRNA booster vaccination in adults older than 65 years.
Fiche publication
Date publication
novembre 2022
Journal
Scientific reports
Auteurs
Membres identifiés du Cancéropôle Est :
Dr MUTTER Catherine
Tous les auteurs :
Durier C, Ninove L, Lefebvre M, Radenne A, Desaint C, Ropers J, Bauer R, Lebbah S, Carette D, Lachatre M, Lecompte AS, Deplanque D, Botelho-Nevers E, Conrad A, Dussol B, Maakaroun-Vermesse Z, Melica G, Nicolas JF, Verdon R, Kiladjian J, Loubet P, Schmidt-Mutter C, Dualé C, Ansart S, Priet S, Levier A, Molino D, Vieillard LV, Parfait B, Lelièvre JD, Tartour E, de Lamballerie X, Launay O, , , , , , ,
Lien Pubmed
Résumé
Immune response induced by COVID-19 vaccine booster against delta and omicron variants was assessed in 65 adults (65-84 years old) early aftesr a first booster dose. An increase in SARS-CoV-2 neutralizing antibodies was shown in individuals not previously infected without evidence of an age-related effect, with lower increase in those infected before a single dose of primary vaccination. Of note, humoral response was observed only starting from the 5th day after the boost.
Mots clés
Humans, Aged, Aged, 80 and over, Antibodies, Neutralizing, SARS-CoV-2, genetics, Neutralization Tests, Antibodies, Viral, RNA, Messenger, Viral Vaccines, COVID-19, prevention & control, Vaccination
Référence
Sci Rep. 2022 11 27;12(1):20373